Biodexa Pharmaceuticals Plc (BDRX)

1.2400 -0.0800 (-6.06%) At close: 04:00PM EDT

Biodexa Pharmaceuticals Plc

1 Caspian Point
Caspian Way
Cardiff CF10 4DQ
United Kingdom
44 29 2048 0180
https://www.biodexapharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 21

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Stephen A. Stamp	CEO, CFO, Company Secretary & Director	315.96k	N/A	1962
Dr. Dmitry Zamoryakhin M.D.	Chief Scientific Officer & Chief Medical Officer	298.85k	N/A	1980
Dr. Daniel Palmer MBA, Ph.D.	Vice President of Technology	N/A	N/A	N/A
Ms. Nicola Tuckwell	VP & Head of Clinical Operations	N/A	N/A	N/A
Ms. Fiona Sharp	Group Financial Controller	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Corporate governance

Biodexa Pharmaceuticals Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.